Premium
ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children
Author(s) -
de Montalembert Mariane,
Ferster Alina,
Colombatti Raffaella,
Rees David C.,
Gulbis Beatrice
Publication year - 2011
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21865
Subject(s) - medicine , pediatrics , pneumococcal vaccine , incidence (geometry) , penicillin , population , disease , pneumococcal polysaccharide vaccine , sickle cell anemia , streptococcus pneumoniae , pneumococcal disease , antibiotics , biology , physics , environmental health , optics , microbiology and biotechnology
Universal neonatal screening is performed in the United States, England, the Netherlands, and several cities in Belgium, with selective screening targeted on "high-risk" population in France (globally, one quarter of all the babies born in France are screened). Newborns diagnosed with a major sickle cell syndrome (SCD) should be referred to a designated pediatric sickle cell centre, and the parents are informed that their child has SCD; this may be in the sickle cell centre by an expert physician or in the community by an experienced nurse counsellor. The pediatric sickle cell centre should organize the care of the baby.